Title:Follow-up Comparisons of Two Plasma Biomarkers of Alzheimer’s
Disease, Neurofilament Light Chain, and Oligomeric Aβ: A Pilot Study
Volume: 20
Issue: 10
Author(s): YongSoo Shim*
Affiliation:
- Department of Neurology, The Catholic University of Korea Eunpyeong St. Mary’s Hospital, Seoul, Republic of Korea
Keywords:
Alzheimer’s disease, neurofilament light protein, multimer detection system-oligomeric Aβ, plasma, biomarker, mild cognitive impairment.
Abstract:
Background and Objective: Recent evidence suggests that blood-based biomarkers
might be useful for Alzheimer’s disease (AD). Among them, we intend to investigate whether neurofilament
light (NfL) and multimer detection system-oligomeric Aβ (MDS-OAβ) values can be
useful in screening, predicting, and monitoring disease progression and how the relationship between
NfL and MDS-OAβ values changes.
Methods: Eighty participants with probable AD dementia, 50 with mild cognitive impairment
(MCI), and 19 with subjective cognitive decline (SCD) underwent baseline and follow-up evaluations
of the Mini-Mental Status Examination (MMSE) and both plasma biomarkers.
Results: Baseline MDS-OAß (p = 0.016) and NfL (p = 0.002) plasma concentrations differed significantly
among groups, but only NfL correlated with baseline MMSE scores (r = -0.278, p =
0.001). In follow-up, neither correlated with MMSE changes overall. However, in SCD and MCI
participants (n = 32), baseline MDS-OAß correlated with follow-up MMSE scores (r = 0.532, p =
0.041). Linear regression revealed a relationship between baseline MDS-OAβ and follow-up
MMSE scores. In SCD and MCI participants, plasma NfL changes correlated with MMSE changes
(r = 0.564, p = 0.028).
Conclusion: This study shows that only in participants with SCD and MCI, not including AD dementia,
can MDS-OAß predict the longitudinal cognitive decline measured by follow-up MMSE.
Changes of NfL, not MDS-OAß, parallel the changes of MMSE. Further studies with larger samples
and longer durations could strengthen these results..
